top of page
  • InduQin

Covaxin showed 81% interim efficacy: Bharat Biotech on Phase 3 results


Bharat Biotech's homegrown Covid-19 vaccineç Covaxin, has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Hyderabad-based company said on Wednesday. That’s better than Bharat Biotech’s guidance last year of around 60% and India’s benchmark of 50% for vaccines targeting the novel coronavirus.


The trials involved 25,800 participants and was conducted in partnership with Indian Council of Medical Research (ICMR), the Indian government's medical research body. This was the largest ever trial conducted in India. "The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 2,433 over the age of 60 and 4,500 with comorbidities," the company said in a statement.


"Today is an important milestone in vaccine discovery, for science and our fight against coronavirus. With today's results from our Phase 3 clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2, and 3 trials involving around 27,000 participants," Bharat Biotech Chairman and Managing Director Krishna Ella said.


Read More at https://www.business-standard.com/article/current-affairs/covaxin-showed-81-interim-efficacy-bharat-biotech-on-phase-3-results-121030300966_1.html

1 view0 comments

Comentários


bottom of page